ApicHope Pharmaceutical Co.,Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | ApicHope (300723. SZ) was founded in 2002 and listed on the Shenzhen Stock Exchange in 2017. It currently employs 1700 people and is headquartered on Guangzhou International Biological Island. It is an innovative biopharmaceutical enterprise focused on the fields of children's medicine, chronic disease medicine, and biological gene vaccines. Yipinhong has built an office headquarters with an area of over 50000 square meters, an innovative research and development center with an area of over 60000 square meters, a digital production base with an area of 220000 square meters that meets EU and FDA standards, and a 110 acre raw material drug production base under construction. The entire pharmaceutical industry chain layout has been completed. Poinsettia has formed a 330 person innovative research and development team led by a senior global chief scientist. From 2021 to 2022, the R&D investment will be approximately 1 billion yuan, accounting for over 10% of the annual revenue. We currently have 179 registration approvals, and in 2022, the number of new drug registration approvals ranked among the top 10 in the domestic industry, ranking first in Guangdong for two consecutive years. Global synchronization of three major technology platforms: Children's Medicine High end Formulation Technology Platform: With 27 existing products and 29 ongoing children's medicine projects, including 5 children's vaccines, it will become the strongest and largest enterprise in the field of children's medicine in China. Slow disease drug innovation research and development platform: Key project - the world's first innovative gout drug AR882: has completed global multicenter Phase II clinical trials, and compared to all first-line or under research gout drugs, it has better efficacy and safety. It is currently the best gout drug in the world, and is expected to bring more than $5 billion in output value after the product is launched. Biological Gene Vaccine Technology Platform: Key Project - Recombinant Protein Tetravalent Influenza Vaccine Based on Insect Cell Expression: For the Sainovi Tetravalent Influenza Vaccine, the effectiveness is consistent and the safety is better. The IND application will be conducted in October 2023. In 2022, the revenue of Sanofi quadrivalent influenza vaccine products was 2.9 billion euros. Yipinhong, in collaboration with the China Song Qingling Foundation, has jointly established the China Song Qingling Foundation Yipinhong Children's Health and Love Special Fund. It actively carries out various poverty alleviation, education donation, and flood relief activities, fulfilling the mission of the times, benefiting patients, and giving back to society. |
| Headquarter | Guangzhou |
| Establish Date | 2/4/2002 |
| Listed Code | 300723.SZ |
| Listed Date | 11/16/2017 |
| Chairman | Li Hanxiong. |
| CEO | Li Hanxiong. |
| Website | www.apichope.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
